

APC anti-mouse CD274 (B7-H1, PD-L1) Antibody

Catalog# / Size	124311 / 25 µg 124312 / 100 µg
Clone	10F.9G2
Regulatory Status	RUO
Other Names	B7-H1, PD-L1
Isotype	Rat IgG2b, κ
Description	CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Red Laser (633 nm)
Application Notes	Additional reported applications (for the relevant formats) include: immunofluorescence ⁴ , blocking ^{6,7,8,9} , and immunohistochemistry of acetone-fixed frozen sections ^{4, 11} . The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Application References	<ol style="list-style-type: none"> Maier H, <i>et al.</i> 2007. <i>J. Immunol.</i> 178:2714. Meng Q, <i>et al.</i> 2006. <i>Invest. Ophthalmol. Vis. Sci.</i> 47:4444. PubMed Scarlett UK, <i>et al.</i> 2012. <i>J Exp Med.</i> 209:495. PubMed Grabie N, <i>et al.</i> 2007. <i>Circulation</i> 116:2062. (IF, IHC) Paterson AM, <i>et al.</i> 2011. <i>J. Immunol.</i> 187:1097. Channappanavar R, <i>et al.</i> 2012. <i>PLoS One</i> 7:e39757. (Block) Schreiber HA, <i>et al.</i> 2010. <i>PLoS One</i> 5:e11453. (Block) PubMed Muthumani K, <i>et al.</i> 2011. <i>J. Immunol.</i> 187:2932. (Block) PubMed Cripps JG, <i>et al.</i> 2010. <i>Hepatology</i> 52:1350. (Block) PubMed Murakami R, <i>et al.</i> 2013. <i>PLoS One.</i> 8:73270. PubMed
(PubMed link indicates BioLegend citation)	

11. Riella LV, *et al.* 2011. *Am. J. Transplant* 11:832-40. (IHC)
12. Lei GS, *et al.* 2015. *Infect Immun.* 83:572. [PubMed](#)

Product Citations

1. Ngjow S, *et al.* 2016. *Cancer Res.* 76: 6266 - 6277. [PubMed](#)
2. Saha D *et al.* 2017. *Cancer cell.* 32(2):253-267. [PubMed](#)
3. Chan LC, *et al.* 2019. *J Clin Invest.* 129:3324. [PubMed](#)
4. Yonemitsu K, *et al.* 2022. *Sci Rep.* 12:12007. [PubMed](#)
5. Tatsuguchi T, *et al.* 2022. *Int Immunol.* 34:277. [PubMed](#)
6. Khan KA, *et al.* 2020. *NPJ Breast Cancer.* 6:29. [PubMed](#)
7. Pierini S, *et al.* 2021. *J Immunother Cancer.* 9:. [PubMed](#)
8. Park S, *et al.* 2021. *Front Immunol.* 11:620166. [PubMed](#)
9. Kiritsy MC, *et al.* 2021. *Elife.* 10:. [PubMed](#)
10. Aguilera T, *et al.* 2016. *Nat Commun.* 7:13898. [PubMed](#)
11. Zhang Y, *et al.* 2020. *Oncol Lett.* 1.053472222. [PubMed](#)
12. Kim TJ, *et al.* 2019. *Nat Commun.* 10:3258. [PubMed](#)
13. Lin R, *et al.* 2020. *Sci Rep.* 10:14397. [PubMed](#)
14. Zhang C, *et al.* 2022. *J Extracell Vesicles.* 11:e12209. [PubMed](#)
15. Ren J, *et al.* 2021. *Theranostics.* 11:304. [PubMed](#)
16. Chen L, *et al.* 2020. *Cancer Immunol Res.* 0.457638889. [PubMed](#)
17. Fu Y, *et al.* 2020. *Sci Rep.* 10:9027. [PubMed](#)
18. Choi H *et al.* 2019. *Cell Rep.* 27(3):806-819. [PubMed](#)
19. Bommireddy R, *et al.* 2020. *Vaccines (Basel).* 8:. [PubMed](#)
20. Findlay EG, *et al.* 2019. *Oncoimmunology.* 8:1608106. [PubMed](#)
21. Cousin N, *et al.* 2021. *Cancer Res.* 81:4133. [PubMed](#)
22. Zhang C, *et al.* 2020. *Cell Metabolism.* 31(1):148-161.e5.. [PubMed](#)
23. Zhou KX, *et al.* 2021. *J Immunol Res.* 2021:6694392. [PubMed](#)
24. Tu J, *et al.* 2022. *Theranostics.* 12:747. [PubMed](#)
25. Davidson S, *et al.* 2020. *Cell Reports.* 31(7):107628. [PubMed](#)
26. Pein M, *et al.* 2020. *Nat Commun.* 11:1494. [PubMed](#)
27. Khan KA, *et al.* 2020. *NPJ Breast Cancer.* 6:29. [PubMed](#)
28. Zhang P, *et al.* 2022. *BMC Med.* 20:435. [PubMed](#)
29. Guo L, *et al.* 2021. *Front Immunol.* 12:785457. [PubMed](#)
30. Lovisa S, *et al.* 2020. *Sci Signal.* 13:00. [PubMed](#)
31. Zhou L, *et al.* 2020. *Clin Cancer Res.* 26:290. [PubMed](#)
32. Hu Q, *et al.* 2018. *Nat Biomed Eng.* 0.660416667. [PubMed](#)
33. Kennedy EM, *et al.* 2022. *Nat Commun.* 13:5907. [PubMed](#)
34. Pradhan K, *et al.* 2021. *Front Immunol.* 12:778830. [PubMed](#)
35. Poon E, *et al.* 2017. *J Immunother Cancer.* 10.1186/s40425-017-0268-8. [PubMed](#)
36. Holokai L, *et al.* 2020. *Cancers (Basel).* 12:00. [PubMed](#)
37. Rashid MH, *et al.* 2021. *Oncol Rep.* 45:1171. [PubMed](#)
38. Huang L, *et al.* 2021. *Breast Cancer Res Treat.* Online ahead of print. [PubMed](#)
39. Koikawa K, *et al.* 2021. *Cell.* 184(18):4753-4771.e27. [PubMed](#)
40. Vardhana SA, *et al.* 2020. *Nat Immunol.* 1.584722222. [PubMed](#)
41. Ying Zhang *et al.* 2017. *Cancer cell.* 32(3):377-391. [PubMed](#)
42. Zhang X, *et al.* 2021. *Mol Cancer Res.* 19:1076. [PubMed](#)
43. Almishri W, *et al.* 2015. *J Hepatol.* 63: 943-951. [PubMed](#)
44. Fukumoto T, *et al.* 2019. *Cancer Res.* 79:5482. [PubMed](#)
45. Yuan M, *et al.* 2022. *Oxid Med Cell Longev.* 2022:5479491. [PubMed](#)
46. Shen ZY, *et al.* 2021. *Front Immunol.* 12:589200. [PubMed](#)
47. Williams JB, *et al.* 2020. *Nat Commun.* 0.876388889. [PubMed](#)
48. Franklin DA, *et al.* 2020. *JCI Insight.* 5:. [PubMed](#)
49. Baldwin LA, *et al.* 2022. *Nat Commun.* 13:6539. [PubMed](#)
50. Barbet G, *et al.* 2018. *Immunity.* 48:584. [PubMed](#)
51. iwata TN, *et al.* 2018. *Mol Cancer Ther.* 17:1494. [PubMed](#)
52. Yi M, *et al.* 2022. *J Hematol Oncol.* 15:142. [PubMed](#)
53. Li Q, *et al.* 2022. *Front Oncol.* 12:841977. [PubMed](#)
54. Lindhorst A, *et al.* 2021. *Cell Death Dis.* 12:579. [PubMed](#)
55. Vogel A, *et al.* 2022. *Cell Rep.* 38:110420. [PubMed](#)
56. Wang R, *et al.* 2022. *J Immunother Cancer.* 10:. [PubMed](#)
57. Kataru RP, *et al.* 2019. *Cancer Immunol Res.* 7:1345. [PubMed](#)
58. Renner K, *et al.* 2020. *Cell Reports.* 29(1):135-150.e9.. [PubMed](#)
59. Zheng C, *et al.* 2022. *Acta Pharm Sin B.* 12:3726. [PubMed](#)
60. Shen H, *et al.* 2022. *Nat Commun.* 13:5013. [PubMed](#)
61. Lin J, *et al.* 2021. *Cancer Immunol Res.* 9:1413. [PubMed](#)
62. Liu YS, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
63. Luna-Yolba R, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
64. Freed-Pastor WA, *et al.* 2021. *Cancer Cell.* .: [PubMed](#)
65. Wang C, *et al.* 2018. *Sci Transl Med.* 10. [PubMed](#)
66. Shaashua L, *et al.* 2022. *Nat Commun.* 13:6513. [PubMed](#)
67. RL M, *et al.* 2015. *Proc Natl Acad Sci U S A.* 112:6506-6514. [PubMed](#)
68. Lerbs T, *et al.* 2020. *JCI Insight.* 5:00. [PubMed](#)
69. Li CY, *et al.* 2022. *Int J Mol Sci.* 23:. [PubMed](#)
70. Song X, *et al.* 2022. *Transl Oncol.* 15:101306. [PubMed](#)
71. Luo N, *et al.* 2018. *Nat Commun.* 0.547222222. [PubMed](#)

RRID

AB_10612935 (BioLegend Cat. No. 124311)
 AB_10612741 (BioLegend Cat. No. 124312)

Antigen Details

Structure	40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution	T cells, B cells, NK cells, dendritic cells, IFN- γ activated endothelial cells, and monocytes
Ligand/Receptor	PD-1 (PDCD1)
Cell Type	B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area	Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family	Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References	1. Sharpe A, <i>et al.</i> 2007. <i>Nat. Immunol.</i> 8:239. 2. Dong H, <i>et al.</i> 1999. <i>Nat. Med.</i> 5:1365. 3. Freeman G, <i>et al.</i> 2000. <i>J. Exp. Med.</i> 192:1027.
Gene ID	60533


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

Purified anti-mouse CD274 (B7-H1, PD-L1), Biotin anti-mouse CD274 (B7-H1, PD-L1), PE anti-mouse CD274 (B7-H1, PD-L1), Brilliant Violet 421™ anti-mouse CD274 (B7-H1, PD-L1), APC anti-mouse CD274 (B7-H1, PD-L1), PE/Cyanine7 anti-mouse CD274 (B7-H1, PD-L1), Ultra-LEAF™ Purified anti-mouse CD274 (B7-H1, PD-L1), Brilliant Violet 711™ anti-mouse CD274 (B7-H1, PD-L1), Brilliant Violet 605™ anti-mouse CD274 (B7-H1, PD-L1), PE/Dazzle™ 594 anti-mouse CD274 (B7-H1, PD-L1), GoInVivo™ Purified anti-mouse CD274 (B7-H1, PD-L1), Brilliant Violet 785™ anti-mouse CD274 (B7-H1, PD-L1), PerCP/Cyanine5.5 anti-mouse CD274 (B7-H1, PD-L1), Brilliant Violet 650™ anti-mouse CD274 (B7-H1, PD-L1), PE/Cyanine5 anti-mouse CD274 (B7-H1, PD-L1), PE/Fire™ 640 anti-mouse CD274 (B7-H1, PD-L1), Spark Red™ 718 anti-mouse CD274 (B7-H1, PD-L1)

Product Data



C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) APC (pink line) or rat IgG2b, κ APC (purple line).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

